ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,101.24
-0.29%
US Tech 100
21,156.80
-0.70%
다우존스 지수
44,424.25
-0.32%
Bitcoin
105,212.43
0.46%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Verve Therapeutics Inc (VERV) 시세

Verve Therapeutics Inc

Verve Therapeutics Inc (VERV)

Verbund Ag
Verbund Ag
Verbund Ag
Verbund Ag
7.91
-0.08
(-1.00%)
마감 27 1월 6:00AM
15분 지연
7.95
0.04
(0.51%)
시간외 거래: 9:35AM
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

주요 통계 및 세부정보

가격
7.95
매수가
7.88
매도가
8.30
거래량
2,263,819
7.81 일간 변동폭 8.535
4.305 52주 범위 19.34
market_cap
673.078M
전일 종가
7.99
개장가
7.99
최근 거래 시간
1
@
7.95
마지막 거래 시간
재정 규모
US$ 18,372,075
VWAP
8.1155
평균 볼륨(3m)
1,655,851
발행 주식
84,663,840
배당수익률
-
주가수익률
-3.35
주당순이익(EPS)
-2.36
매출
11.76M
순이익
-200.07M

Verve Therapeutics Inc 정보

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.vervetx.com
본부
Wilmington, Delaware, USA
설립됨
-
Verve Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker VERV. The last closing price for Verve Therapeutics was US$7.99. Over the last year, Verve Therapeutics shares have traded in a share price range of US$ 4.305 to US$ 19.34.

Verve Therapeutics currently has 84,663,840 shares in issue. The market capitalisation of Verve Therapeutics is US$676.46 million. Verve Therapeutics has a price to earnings ratio (PE ratio) of -3.35.

VERV 최신 뉴스

추가 뉴스

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301...

13 1월 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

10 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 1월 2025
Edgar (US Regulatory)

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar...

08 1월 2025
GlobeNewswire Inc.

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December...

04 1월 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

05 12월 2024
Edgar (US Regulatory)

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November...

30 11월 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

09 11월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
11.8430.11456628486.118.26.09527953427.1636568CS
41.7127.40384615386.248.25.18915937316.28491415CS
122.2238.74345549745.738.24.4416558516.00196451CS
260.273.5156257.688.24.30514533395.72604662CS
52-4.37-35.470779220812.3219.344.30513905407.12495272CS
156-24.03-75.140712945631.98434.305108296414.54308418CS
260-22.05-73.530784.30598005617.09587409CS

VERV - Frequently Asked Questions (FAQ)

What is the current Verve Therapeutics share price?
The current share price of Verve Therapeutics is US$ 7.95
How many Verve Therapeutics shares are in issue?
Verve Therapeutics has 84,663,840 shares in issue
What is the market cap of Verve Therapeutics?
The market capitalisation of Verve Therapeutics is USD 676.46M
What is the 1 year trading range for Verve Therapeutics share price?
Verve Therapeutics has traded in the range of US$ 4.305 to US$ 19.34 during the past year
What is the PE ratio of Verve Therapeutics?
The price to earnings ratio of Verve Therapeutics is -3.35
What is the cash to sales ratio of Verve Therapeutics?
The cash to sales ratio of Verve Therapeutics is 56.95
What is the reporting currency for Verve Therapeutics?
Verve Therapeutics reports financial results in USD
What is the latest annual turnover for Verve Therapeutics?
The latest annual turnover of Verve Therapeutics is USD 11.76M
What is the latest annual profit for Verve Therapeutics?
The latest annual profit of Verve Therapeutics is USD -200.07M
What is the registered address of Verve Therapeutics?
The registered address for Verve Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Verve Therapeutics website address?
The website address for Verve Therapeutics is www.vervetx.com
Which industry sector does Verve Therapeutics operate in?
Verve Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

VERV Discussion

게시물 보기
Monksdream Monksdream 5 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 5 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 6 월 전
VERV 10Q due AUGUST5
👍️0
Monksdream Monksdream 7 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 7 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 8 월 전
VERV more new lows up ahead
👍️0
Monksdream Monksdream 8 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 9 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 9 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 9 월 전
VERV new 52 week low
👍️0
Monksdream Monksdream 9 월 전
VERV new 52 lo
👍️0
Firestorm22 Firestorm22 10 월 전
uh oh
👍️0
Monksdream Monksdream 10 월 전
VERV over $10
👍️0
fink fink 11 월 전
Looking for an entry now
👍️0
Terpi Terpi 1 년 전
Could see another nice move here is the 50 day holds into close.
👍️0
Monksdream Monksdream 1 년 전
VERV morning rally
👍️0
TheFinalCD TheFinalCD 2 년 전
https://cathiesark.com/
👍️0
crudeoil24 crudeoil24 3 년 전
VERV IS A GREAT $$$$$ OPPORTUNITY.
👍️0
crudeoil24 crudeoil24 3 년 전
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
👍️0
crudeoil24 crudeoil24 3 년 전
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
👍️0

최근 히스토리

NASDAQ
VERV
Verve Therapeutics
BIT
5MIB
GraniteShares 5x Long MI...
BIT
UC5676
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유